BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Press Releases

  Chemed Corporation to Present at the Jefferies 2026 Healthcare Services Conference

  September 8, 2026

   · 

  1 min read
• Press Releases

  Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  September 8, 2026

   · 

  3 min read
• Press Releases

  Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

  September 8, 2026

   · 

  5 min read
• Press Releases

  ME Therapeutics Advances In Vivo CAR and Therapeutic mRNA STING Programs

  September 8, 2026

   · 

  6 min read
• Press Releases

  Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

  September 8, 2026

   · 

  1 min read
• Press Releases

  IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

  September 8, 2026

   · 

  19 min read
• Press Releases

  Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

  September 8, 2026

   · 

  4 min read
• 

  cardiovascular disease

  Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’

  After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile cardiovascular flops to six over nine weeks.

  September 8, 2026

   · 

  2 min read

   · 

  Gabrielle Masson
• 

  Drug Development

  Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data

  Mosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, ‘significantly exceeded expectations’ in reducing pulmonary vascular resistance, according to analysts, and is progressing to a late-stage study.

  September 8, 2026

   · 

  1 min read

   · 

  Michael Gibney
• Press Releases

  Altesa BioSciences Presents Novel Clinical Data Demonstrating Vapendavir Significantly Reduces Key Inflammatory Biomarkers in Rhinovirus-Challenged COPD Patients at the European Respiratory Society International Congress 2026

  September 8, 2026

   · 

  4 min read